Dr. Konduri on Sequencing Therapy in EGFR+ NSCLC

Kartik Konduri, MD
Published: Thursday, Apr 18, 2019



Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer (NSCLC).

Even though osimertinib (Tagrisso) is established as the frontline standard of care in this space, Konduri says that the older-generation EGFR TKIs still have a role in treatment. The question moving forward is where these drugs will fit in as far as sequencing and in which patients they will benefit. Researchers know that agents like erlotinib (Tarceva) and dacomitinib (Vizimpro) can be more effective than other first- and second-generation EGFR TKIs. Konduri says the field will have to sort out whether patients treated with these drugs will develop a secondary T790M resistance mutation that can allow for osimertinib treatment later on.

Moreover, emerging data appear to be positive with the combination of erlotinib and the antiangiogenic agent ramucirumab (Cyramza) as second-line treatment of these patients. As the data read out, the question of where these treatment strategies fit into the paradigm may be more clear.
SELECTED
LANGUAGE


Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer (NSCLC).

Even though osimertinib (Tagrisso) is established as the frontline standard of care in this space, Konduri says that the older-generation EGFR TKIs still have a role in treatment. The question moving forward is where these drugs will fit in as far as sequencing and in which patients they will benefit. Researchers know that agents like erlotinib (Tarceva) and dacomitinib (Vizimpro) can be more effective than other first- and second-generation EGFR TKIs. Konduri says the field will have to sort out whether patients treated with these drugs will develop a secondary T790M resistance mutation that can allow for osimertinib treatment later on.

Moreover, emerging data appear to be positive with the combination of erlotinib and the antiangiogenic agent ramucirumab (Cyramza) as second-line treatment of these patients. As the data read out, the question of where these treatment strategies fit into the paradigm may be more clear.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x